SBFMW — Sunshine Biopharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1402328 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,088,765 | 2,180,990 | -1,395,597 | -1,243,869 | 27,930,375 | 6,913,013 | 6,413,781 |
| Dec 2025 | 8,577,141 | 3,028,845 | -1,658,223 | -2,140,927 | 30,079,167 | 9,123,308 | 7,040,707 |
| Sep 2025 | 9,417,179 | 3,073,540 | -531,963 | -883,820 | 31,487,379 | 9,306,438 | 7,288,023 |
| Jun 2025 | 9,410,230 | 3,422,866 | -992,846 | -1,770,834 | 31,965,250 | 10,305,320 | 6,280,446 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,708,171
Investing CF
$-728,807
Financing CF
$4,393,111
CapEx
$-728,807
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-76,258,995
Inventory
$13,168,430
Receivables
$4,011,632
ST Investments
—
EBIT TTM
$-6,129,408
Pretax Income TTM
$-5,977,680
Interest Exp TTM
$0
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,346,772
EBITDA
$-4,848,974
Free Cash Flow
$-2,011,131
Enterprise Value
—
Total Cash
$14,029,781
Total Debt
$678,338
Shares Out
—
Trailing EPS
$-2.21
Book Value
$43.83
ROE
-21.9%
ROA
-9.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 36,305,891 | -4,478,782 | -5,975,352 | 30,079,167 | 7,040,707 | — | -5,331,073 |
| Dec 2024 | 34,874,283 | -5,812,121 | -5,134,116 | 30,560,392 | 7,059,638 | — | -12,524,779 |
| Dec 2023 | 24,092,787 | -4,785,299 | -4,506,044 | 27,346,961 | 6,139,600 | — | -8,775,111 |
| Dec 2022 | 4,345,603 | -8,674,031 | -26,744,440 | 29,243,848 | 7,616,278 | — | -5,248,358 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.11T | $1246.93 | — |
| JNJ | JOHNSON & JOHNSON | $658.00B | $273.04 | — |
| ABBV | AbbVie Inc. | $467.44B | $264.52 | — |
| MRK | Merck & Co., Inc. | $371.70B | $150.66 | — |
| NVSEF | NOVARTIS AG | $310.96B | $163.60 | — |
News headlines (Yahoo Finance, 1h cache)
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
2026-07-20 12:30 · Yahoo
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
2026-08-19 13:00 · Yahoo
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
2026-08-19 12:30 · Yahoo
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
2026-08-07 13:00 · Yahoo
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
2026-08-04 13:00 · Yahoo
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval
2026-08-04 12:31 · Yahoo
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
2026-07-28 12:00 · Yahoo
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
2026-06-25 12:00 · Yahoo
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
2026-06-01 12:00 · Yahoo
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
2026-06-01 06:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.